ERBB2 and breast carcinoma: This trajectory unequivocally demonstrates how DB-04 has propelled a worldwide transformation in the HER2-low breast cancer therapeutic landscape.DESTINY-Breast04 marks a significant advancement in ADC drugs for breast cancer by targeting the HER2-low expression range.